|
注册号: Registration number: |
ChiCTR2600117382 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-23 09:02:17 |
|
注册时间: Date of Registration: |
2026-01-23 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
儿童青少年近视中西医结合防控:“三级监测”与“三级预警”系统研究 |
|
Public title: |
Integrative Chinese and Western Medicine-Based Prevention and Control for Myopia in Children: A Study on a "Three-Level Monitoring and Three-Level Warning" System |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
儿童青少年近视中西医结合防控:“三级监测”与“三级预警”系统研究 |
|
Scientific title: |
Integrative Chinese and Western Medicine-Based Prevention and Control for Myopia in Children: A Study on a "Three-Level Monitoring and Three-Level Warning" System |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡媛媛 |
研究负责人: |
毕宏生 |
|
Applicant: |
Hu Yuanyuan |
Study leader: |
Bi Hongsheng |
|
申请注册联系人电话: Applicant telephone: |
+86 186 6893 9079 |
研究负责人电话:
Study leader's |
+86 139 5311 3696 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yyhu0616@163.com |
研究负责人电子邮件: Study leader's E-mail: |
hongshengbi1@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市英雄山路48号 |
研究负责人通讯地址: |
山东省济南市英雄山路48号 |
|
Applicant address: |
48 Yingxiongshan Road, Jinan, Shandong, China |
Study leader's address: |
48 Yingxiongshan Road, Jinan, Shandong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
250002 |
研究负责人邮政编码: Study leader's postcode: |
250002 |
|
申请人所在单位: |
山东中医药大学附属眼科医院 |
||
|
Applicant's institution: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
山东中医药大学附属眼科医院 |
||
|
Affiliation of the Leader: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
HEC-HY-2020016-1KY; HEC-HY-2020016-1KY01; HEC-HY-2020016-1KY02; HEC-HY-2020016-1KY03; HEC-HY-2020016-1KY04; HEC-HY-2020016-1KY05 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东中医药大学附属眼科医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-09-06 00:00:00 | ||
|
伦理委员会联系人: |
李晓鹏 |
||
|
Contact Name of the ethic committee: |
Li Xiaopeng |
||
|
伦理委员会联系地址: |
山东省济南市英雄山路48号 |
||
|
Contact Address of the ethic committee: |
48 Yingxiongshan Road, Jinan, Shandong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 5885 9695 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东中医药大学附属眼科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市英雄山路48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
48 Yingxiongshan Road, Jinan, Shandong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and development Program |
||||||||||||||||||||||
|
研究疾病: |
近视 |
||||||||||||||||||||||
|
Target disease: |
Myopia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探究覆盖近视发生发展各阶段的“三级监测”指标,识别并验证关键的动态预警指标;以具有明确生物学意义的预警指标为核心,构建一个分阶段、个体化的“三级预警”动态预测模型,为儿童青少年近视防控提供科学的监测与预警工具。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the "three-level monitoring" indicators covering all stages ; to identify and validate the critical dynamic warning indicators; to construct a staged and individualized "three-level warning" dynamic prediction model based on warning indicators with clear biological significance; and ultimately, to provide a scientific monitoring and warning tool for the prevention and control of myopia in children. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)有斜视、弱视等其他影响视力的眼病史或现病史; (2)有影响眼部发育的全身系统性疾病史; (3)有眼部手术或外伤史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Current or historical diagnosis of any other ocular diseases known to affect vision, including but not limited to strabismus and amblyopia; 2. History of any systemic diseases known to affect ocular development; 3. History of ocular surgery or trauma. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-09-04 00:00:00至 To 2026-09-04 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-09-07 00:00:00 至 To 2020-10-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
不适用 |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
文章发表半年后,ResMan, http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the article was published, ResMan, http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data Collection:Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |